Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2025—Delays while a courier is sent to the blood bank. Errors in judgment. Omission of steps in tracking who received a unit of blood. Wastage of blood product because clinicians were cautious and overordered or ordered too soon. Staffing issues. All of these potential blood bank-related problems can be mitigated with smart blood-storage devices, also called smart refrigerators or blood vending machines.
March 2025
Q. When should plasma mixing tests be performed in the coagulation laboratory, and how are they best interpreted? Read answer.
Q. How important is it for a laboratory to perform whole mount specimen collection and examination? Read answer.
March 2025—The Roche Tina-quant Lipoprotein (a) Gen.2 Molarity assay received 510(k) clearance from the Food and Drug Administration. It is the first 510(k)-cleared test of its kind available in the U.S. to measure lipoprotein(a) in nanomoles per liter. It will be broadly available on Cobas c analyzers. Lp(a) can vary in size and has no single, defined molecular weight. For this reason, Roche says, there is a consensus in the scientific community that Lp(a) levels should be measured in terms of the number of particles per liter of blood (nmol/L), rather than mass units (mg/dL), and that any conversion between mass and molar units is generally imprecise and unreliable. By using molar units, laboratory professionals and clinicians know the Lp(a) measurements reflect the number of particles rather than a difference in particle size.
February 2025—Five years ago, many of us were grappling with the earliest cases of a novel coronavirus in the United States. During the COVID-19 pandemic that ensued, we pathologists became more visible in a variety of ways, both to our clinical colleagues and to the general public.
February 2025—Pulmonary complications cause significant morbidity and mortality in post-hematopoietic stem cell transplantation. The histopathology of pulmonary diseases in the context of post-hematopoietic stem cell transplantation (post-HSCT) is poorly characterized, especially in the pediatric population. The authors sought to characterize the pathologic spectrum of pulmonary disease post-HSCT in a pediatric cohort. Fifty-six specimens, including 53 biopsy specimens, corresponding to 53 patients were identified. Biopsy slides were reviewed and assigned to diagnostic categories (infectious, graft-versus-host disease, vasculopathy, indeterminate, and others) by consensus among three pediatric pulmonary pathologists, taking into consideration pathologic, clinical, radiologic, and laboratory findings.
February 2025—Low titer group O whole blood is commonly used for severe bleeding in trauma patients. It may also benefit pediatric patients undergoing cardiopulmonary bypass who are at risk for massive bleeding and coagulopathies. Circuit anticoagulation, hypothermia, hemodilution, coagulation factor, platelet loss and dysfunction, an underdeveloped hemostasis system in patients younger than two years old, and other factors lead to a higher risk of bleeding. Compared with component therapy, whole blood contains higher concentrations of RBCs, platelets, and coagulation factors, as well as cold platelets with enhanced hemostatic function. Due to the logistical challenges of donor centers providing ABO-specific whole blood for cardiopulmonary bypass (CPB), the use of longer storage-age low titer group O whole blood (LTOWB) may be an option for younger pediatric patients with severe bleeding on CPB.
February 2025—Excision repair cross-complementation group two (ERCC2) is a tumor-suppressor gene involved in DNA repair. Compound heterozygous mutations in ERCC2 are linked to rare recessive disorders, such as xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy, all of which are characterized by ultraviolet light sensitivity. Somatic ERCC2 mutations in cancers, particularly bladder cancers, have emerged as significant prognostic markers. The mutations predict platinum sensitivity and correlate with favorable outcomes in patients with bladder cancer, but they have not been identified as independent prognostic indicators due to a lack of data, resulting from limited cohort sizes. The authors conducted a study in which they investigated the impact of ERCC2 hotspot mutations on genomewide mutagenesis and their implications for cancer prognosis and therapeutic stratification.
February 2025
Q. Is a pathology review on all cerebrospinal fluid (CSF) specimen differential slides necessary? Should the review be based on the number of white blood cells counted or the abnormality of the differential, or both? Read answer.
Q. At what level or time is aPTT considered incorrect? Is an aPTT of less than 22.0 seconds an acceptable result? Read answer.
February 2025—When NYU Langone Health began focusing on digital pathology last year, it also began focusing on people—those it would need to keep such a program humming along. “When we were setting up this operation, it was pretty obvious to me that I wanted to have a dedicated team of people that are going to focus just on digital pathology,” says Rui Soares, anatomic pathology operations director at NYU Langone, a multisite system with approximately 80 pathologists at four hospitals. It would be “unfair,” he adds, to expect laboratory assistants to learn and perform such specialized tasks while performing other duties.
February 2025—Roche’s whole slide imaging system, Roche Digital Pathology Dx, received an additional 510(k) clearance from the Food and Drug Administration. This latest clearance modifies the one Roche received in June 2024 for Roche Digital Pathology Dx, which includes the Ventana DP 200 slide scanner.
